公开(公告)号：US20200010426A1

公开(公告)日：2020-01-09

申请号：US16571405

申请日：2019-09-16

申请人： Novartis AG

发明人： Daniela Angst ,  Francois Gessier ,  Anna Vulpetti

IPC分类号： C07D239/47 ,  A61K31/506 ,  A61K31/505 ,  A61P35/02 ,  A61P29/00 ,  C07D405/12 ,  C07D401/12 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12

摘要： The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US11673868B2

公开(公告)日：2023-06-13

申请号：US17508054

申请日：2021-10-22

申请人： Novartis AG

发明人： Daniela Angst ,  François Gessier ,  Anna Vulpetti

IPC分类号： C07D405/12 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506 ,  C07D239/47 ,  C07D401/14 ,  C07D401/10 ,  C07D401/12 ,  A61P29/00 ,  A61P35/02

CPC分类号： C07D239/47 ,  A61K31/505 ,  A61K31/506 ,  A61P29/00 ,  A61P35/02 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12

摘要： The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US10457647B2

公开(公告)日：2019-10-29

申请号：US15974190

申请日：2018-05-08

申请人： Novartis AG

发明人： Daniela Angst ,  Francois Gessier ,  Anna Vulpetti

IPC分类号： C07D405/12 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506 ,  C07D239/47 ,  C07D401/14 ,  C07D401/10 ,  C07D401/12 ,  A61P29/00 ,  A61P35/02

摘要： The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US12129246B1

公开(公告)日：2024-10-29

申请号：US18589841

申请日：2024-02-28

申请人： Novartis AG

发明人： Daniela Angst ,  Philippe Bolduc ,  Matthew William Carson ,  Atwood Kim Cheung ,  Véronique Darsigny ,  Xiang Gao ,  Viktor Hornak ,  Keith Jendza ,  Rajesh Karki ,  Ajay Kumar Lal ,  Gang Liu ,  Justin Yik Ching Mao ,  Jeffrey M. McKenna ,  Erik Meredith ,  Muneto Mogi ,  Vivek Rauniyar ,  Liansheng Su ,  Ritesh Tichkule ,  Shuangxi Wang ,  Chun Zhang ,  Liang Zhao ,  Rui Zheng

IPC分类号： C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

摘要： The disclosure relates to a compound of Formula (I):




or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.

公开(公告)号：US11180460B2

公开(公告)日：2021-11-23

申请号：US16571405

申请日：2019-09-16

申请人： Novartis AG

发明人： Daniela Angst ,  Francois Gessier ,  Anna Vulpetti

IPC分类号： C07D405/12 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506 ,  A61P19/02 ,  C07D239/47 ,  C07D401/14 ,  C07D401/10 ,  C07D401/12 ,  A61P29/00 ,  A61P35/02

摘要： The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US20180140602A1

公开(公告)日：2018-05-24

申请号：US15564463

申请日：2016-04-07

申请人： Daniela Angst ,  John Byrd ,  Jason Dubovsky ,  Joseph A. Fraietta ,  Francois Gessier ,  Saar Gill ,  Amy Johnson ,  Carl H. June ,  Marcela Maus ,  Natarajan Muthusamy ,  David L. Porter ,  Marco Ruella ,  Anna Vulpetti ,  Mariusz Wasik ,  Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Daniela Angst ,  John Byrd ,  Jason Dubovsky ,  Joseph A. Fraietta ,  Francois Gessier ,  Saar Gill ,  Amy Johnson ,  Carl H. June ,  Marcela Maus ,  Natarajan Muthusamy ,  David L. Porter ,  Marco Ruella ,  Anna Vulpetti ,  Mariusz Wasik

IPC分类号： A61K31/505 ,  A61K35/17 ,  C07K16/28 ,  A61K31/506 ,  C07K16/30 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  A61K2300/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.